Prostate cancer is the second most prevalent cancer among men and may be associated with several risk factors, including sexually transmitted infections (STIs) such as HPV. Although its oncogenic role is already well established in other tissues, the relationship between HPV and prostate cancer remains uncertain. In this context, the present study aims to describe the epidemiological profile of patients with benign prostatic hyperplasia and malignant prostate neoplasms in the Northern region of Brazil, based exclusively on clinical and epidemiological data such as age, history of STIs, and case distribution. This is a descriptive, cross-sectional study conducted with male patients who were referred for transrectal prostate biopsy at a public hospital in the Northern region of Brazil. The study methodology included the collection of tissue samples through transrectal prostate biopsy, which enabled the classification of cases into benign and malignant, as well as the application of an epidemiological questionnaire covering variables such as age, race, marital status, education level, sexual activity, number of sexual partners, condom use, history of STIs, alcohol consumption, and smoking habits. All participants voluntarily agreed to take part in the study and signed an informed consent form. The study was approved by the Research Ethics Committee under protocol number 5.382.448. A total of 54 patients aged between 46 and 90 years were included. Among them, 31 were diagnosed with benign prostatic hyperplasia (58.5%) and 23 with prostate cancer (41.5%). Regarding marital status, 72.2% were in stable relationships, 20.4% were single or divorced, and 7.4% were widowed. Most had completed high school (63%) and identified as white (46.3%). About 63% of participants reported not using condoms, although 92.6% stated they had a fixed partner and 75.9% reported having an active sex life. In terms of substance use, 63.5% consumed alcohol occasionally and 68.5% were non-smokers. Regarding STIs, 66.5% denied any history, but among those who reported infections, HPV was the most frequent (18.5%). These findings provide an overview of the profile of patients with prostatic alterations, highlighting that the majority were older men, in stable relationships, with a medium level of education and predominantly white. Despite reporting fixed partners and active sexual lives, condom use was low, and a significant proportion had a history of STIs, particularly HPV. These aspects emphasize the relevance of investigating possible correlations between STIs—especially HPV—and prostatic diseases, and the importance of implementing preventive strategies and health education targeting this male population.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
